CMS Grants NTAP for Boston Scientific AGENT™ Drug-Coated Balloon
News from Boston Scientific
Boston Scientific announced that the U.S. Centers for Medicare & Medicaid Services (CMS) granted a New Technology Add-on Payment (NTAP) for the AGENT™ Drug-Coated Balloon (DCB). NTAP was created to facilitate patient access for qualifying new medical technologies that substantially improve the diagnosis or treatment of Medicare beneficiaries.
Beginning October 1, 2025, CMS will provide hospitals with additional device reimbursement when the AGENT DCB is used for eligible cases in the hospital inpatient setting.
- Approved in the U.S. in 2024, AGENT DCB is the first drug-coated coronary balloon in the U.S. and is a dedicated treatment for coronary in-stent restenosis (ISR) in patients with coronary artery disease, and is an alternative treatment to conventional balloon angioplasty.
- The AGENT DCB is also commercially available in many international markets and has been used to treat more than 100,000 patients globally.
“The CMS determination is a positive development for patients with in-stent restenosis and supports clinical findings that the AGENT DCB is statistically superior to conventional balloon angioplasty for treating the condition,” said Lance Bates, senior vice president and president, Interventional Cardiology Therapies, Boston Scientific. “We applaud this ruling as it will allow hospitals to receive additional reimbursement when treating patients with the device, supporting access to the AGENT DCB for Medicare beneficiaries.”
Find More:
Renal Denervation Topic Center
Cardiovascular Ambulatory Surgery Centers (ASCs) Topic Center
Grand Rounds With Morton Kern, MD
Peripheral Artery Disease Topic Center
Podcasts: Cath Lab Conversations
